Key result
Versican promotes cardiomyocyte proliferation, reduces fibrosis, and improves post-MI cardiac function in mice.
Why the study?
Whether and how cardiac fibroblast expansion and extracellular matrix compositional changes after neonatal myocardial injury influence cardiomyocyte proliferation and heart regeneration remained unknown.
Does versican promote cardiomyocyte proliferation and cardiac repair in models of myocardial injury?
Does versican promote cardiomyocyte proliferation and cardiac repair in models of myocardial injury?
Versican acts as a pro-proliferative proteoglycan that promotes cardiomyocyte proliferation and cardiac repair via integrin β1 signaling, highlighting its potential as a therapeutic factor for ischemic heart diseases.
No takes yet. Share an insight, caveat, or question.
Supports versican investigation for post-MI regeneration; leaves open human therapeutic translation.
Feng et al. (2023) studied Myocardial injury / Myocardial infarction. Versican was evaluated on Cardiomyocyte proliferation and cardiac repair. Versican, a cardiac fibroblast-derived extracellular matrix component, promoted cardiomyocyte proliferation, reduced fibrosis, and improved cardiac function after myocardial infarction in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: